WO2006003222A9 - Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras - Google Patents

Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras Download PDF

Info

Publication number
WO2006003222A9
WO2006003222A9 PCT/ES2005/000365 ES2005000365W WO2006003222A9 WO 2006003222 A9 WO2006003222 A9 WO 2006003222A9 ES 2005000365 W ES2005000365 W ES 2005000365W WO 2006003222 A9 WO2006003222 A9 WO 2006003222A9
Authority
WO
WIPO (PCT)
Prior art keywords
formoterol
prophylactic
infections
diabetes
aids
Prior art date
Application number
PCT/ES2005/000365
Other languages
English (en)
French (fr)
Other versions
WO2006003222A1 (es
Inventor
Huguet Jose Maria Argiles
Soriano Francisco Javier Lopez
Rius Silvia Busquets
Original Assignee
Univ Barcelona
Huguet Jose Maria Argiles
Soriano Francisco Javier Lopez
Rius Silvia Busquets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Barcelona, Huguet Jose Maria Argiles, Soriano Francisco Javier Lopez, Rius Silvia Busquets filed Critical Univ Barcelona
Priority to DK05763090.7T priority Critical patent/DK1818052T3/da
Priority to EP05763090A priority patent/EP1818052B1/en
Priority to DE602005017659T priority patent/DE602005017659D1/de
Priority to PL05763090T priority patent/PL1818052T3/pl
Priority to AT05763090T priority patent/ATE447944T1/de
Publication of WO2006003222A1 publication Critical patent/WO2006003222A1/es
Publication of WO2006003222A9 publication Critical patent/WO2006003222A9/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

El formoterol, utilizado hasta ahora para el tratamiento del broncoespasmo asociado a asma, exhibe una potente eficiencia anti-caquéctica con relativamente bajos efectos secundarios adversos y toxicidad. Así, la invención se refiere al use del formoterol o sus sales o solvatos farmacéuticamente aceptables, particularmente fumarato o fumarato dihidrato, para la preparación de un medicamento para el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o un síndrome caquéctico, ambos asociados a un estado catabólico en un mamífero, en particular un humano. Algunos estados catabólicos que se pueden tratar con formoterol son cáncer, el síndrome de la inmunodeficiencia adquirida (SIDA), infecciones, diabetes, estados de inmovilización o distrofias musculares.
PCT/ES2005/000365 2004-06-29 2005-06-28 Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras WO2006003222A1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK05763090.7T DK1818052T3 (da) 2004-06-29 2005-06-28 Anvendelse af formoterol i den profylaktiske og/eller terapeutiske behandling af muskelsvind og/eller kakektisk syndrom i forbindelse med kataboliske forhold af visse sygdomme såsom cancer, aids, infektioner, diabetes og andre
EP05763090A EP1818052B1 (en) 2004-06-29 2005-06-28 Use of formoterol in the prophylactic and/or therapeutic treatment of muscle wasting and/or cachectic syndrome which are associated with catabolic conditions of certain diseases, such as cancer, aids, infections, diabetes and others
DE602005017659T DE602005017659D1 (de) 2004-06-29 2005-06-28 Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere
PL05763090T PL1818052T3 (pl) 2004-06-29 2005-06-28 Zastosowanie formoterolu w profilaktycznym i/lub terapeutycznym leczeniu wyniszczenia mięśniowego i/lub zespołu wyniszczenia, związanych ze stanami katabolicznymi w przebiegu niektórych chorób, takich jak nowotwory, AIDS, zakażenia, cukrzyca i inne
AT05763090T ATE447944T1 (de) 2004-06-29 2005-06-28 Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200401941 2004-06-29
ES200401941A ES2245612B1 (es) 2004-06-29 2004-06-29 Nuevo uso terapeutico del formoterol.

Publications (2)

Publication Number Publication Date
WO2006003222A1 WO2006003222A1 (es) 2006-01-12
WO2006003222A9 true WO2006003222A9 (es) 2009-01-15

Family

ID=35614437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2005/000365 WO2006003222A1 (es) 2004-06-29 2005-06-28 Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras

Country Status (9)

Country Link
EP (1) EP1818052B1 (es)
AT (1) ATE447944T1 (es)
CY (1) CY1109771T1 (es)
DE (1) DE602005017659D1 (es)
DK (1) DK1818052T3 (es)
ES (2) ES2245612B1 (es)
PL (1) PL1818052T3 (es)
PT (1) PT1818052E (es)
WO (1) WO2006003222A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
MX2009011294A (es) * 2007-04-24 2010-01-29 Acacia Pharma Ltd Combinacion de farmacos y su uso en el tratamiento de la perdida muscular.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
WO2002066021A2 (de) * 2001-02-22 2002-08-29 Universitätsklinikum Charite Medizinische Fakultät Der Humboldt-Universität Zu Berlin Inhibitoren der protein kinase d und der protein kinase 2 als mittel zur hemmung von tumorzellen und zur stimulierung der angiogehese

Also Published As

Publication number Publication date
PT1818052E (pt) 2010-02-15
EP1818052A1 (en) 2007-08-15
DE602005017659D1 (de) 2009-12-24
DK1818052T3 (da) 2010-03-29
PL1818052T3 (pl) 2010-04-30
WO2006003222A1 (es) 2006-01-12
EP1818052B1 (en) 2009-11-11
ES2245612A1 (es) 2006-01-01
ATE447944T1 (de) 2009-11-15
CY1109771T1 (el) 2014-09-10
ES2245612B1 (es) 2007-08-16
ES2336229T3 (es) 2010-04-09

Similar Documents

Publication Publication Date Title
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
DK2170857T3 (da) 3',4',5-trimethoxyflavonderivater som stimulerende middel ved slimafsondring, tilsvarende fremgangsmåde og farmaceutisk præparat, der indeholder disse
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
WO2006003222A9 (es) Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras
PT1670489E (pt) Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
WO2005055956A3 (en) Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
PT1220676E (pt) Prevencao do cancro colorrectal
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
HK1081862A1 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
WO2005107871A3 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
DK1416937T3 (da) Profylaktisk og terapeutisk anvendelse af hydroxysteroider
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
WO2002080889A3 (en) A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer
WO2006017921A8 (en) Selective muscle relaxant and pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005763090

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005763090

Country of ref document: EP